Induction Chemotherapy for Patients With High-Risk or Secondary AML

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Standard for Intensive Induction Therapy: 7+3

Considerations for Older Patients

Typical Results With 7+3

Challenges With Intensive Induction Therapy

Dose Reduction to 5+2

Hypomethylating Agents

Low-Dose (20 mg BID SQ) Cytarabine

Clofarabine

Alternative Formulation: CPX-351

Phase 2 Study of CPX-351

Phase 3 Study of CPX-351

Concluding Remarks

Abbreviations

Abbreviations (cont)